Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

Alexandre Reuben, Christine N. Spencer, Peter A. Prieto, Vancheswaran Gopalakrishnan, Sangeetha M. Reddy, John P. Miller, Xizeng Mao, Mariana Petaccia De Macedo, Jiong Chen, Xingzhi Song, Hong Jiang, Pei Ling Chen, Hannah C. Beird, Haven R. Garber, Whijae Roh, Khalida Wani, Eveline Chen, Cara Haymaker, Marie Andrée Forget, Latasha D. LittleCurtis Gumbs, Rebecca L. Thornton, Courtney W. Hudgens, Wei Shen Chen, Jacob Austin-Breneman, Robert Szczepaniak Sloane, Luigi Nezi, Alexandria P. Cogdill, Chantale Bernatchez, Jason Roszik, Patrick Hwu, Scott E. Woodman, Lynda Chin, Hussein Tawbi, Michael A. Davies, Jeffrey E. Gershenwald, Rodabe N. Amaria, Isabella C. Glitza, Adi Diab, Sapna P. Patel, Jianhua Hu, Jeffrey E. Lee, Elizabeth A. Grimm, Michael T. Tetzlaff, Alexander J. Lazar, Ignacio I. Wistuba, Karen Clise-Dwyer, Brett W. Carter, Jianhua Zhang, P. Andrew Futreal, Padmanee Sharma, James P. Allison, Zachary A. Cooper, Jennifer A. Wargo

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Appreciation for genomic and immune heterogeneity in cancer has grown though the relationship of these factors to treatment response has not been thoroughly elucidated. To better understand this, we studied a large cohort of melanoma patients treated with targeted therapy or immune checkpoint blockade (n = 60). Heterogeneity in therapeutic responses via radiologic assessment was observed in the majority of patients. Synchronous melanoma metastases were analyzed via deep genomic and immune profiling, and revealed substantial genomic and immune heterogeneity in all patients studied, with considerable diversity in T cell frequency, and few shared T cell clones (<8% on average) across the cohort. Variables related to treatment response were identified via these approaches and through novel radiomic assessment. These data yield insight into differential therapeutic responses to targeted therapy and immune checkpoint blockade in melanoma, and have key translational implications in the age of precision medicine.

Original languageEnglish (US)
Article number10
Journalnpj Genomic Medicine
Volume2
Issue number1
DOIs
StatePublished - Dec 1 2017
Externally publishedYes

Fingerprint

Melanoma
Therapeutics
T-Lymphocytes
Precision Medicine
Clone Cells
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., ... Wargo, J. A. (2017). Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. npj Genomic Medicine, 2(1), [10]. https://doi.org/10.1038/s41525-017-0013-8

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. / Reuben, Alexandre; Spencer, Christine N.; Prieto, Peter A.; Gopalakrishnan, Vancheswaran; Reddy, Sangeetha M.; Miller, John P.; Mao, Xizeng; De Macedo, Mariana Petaccia; Chen, Jiong; Song, Xingzhi; Jiang, Hong; Chen, Pei Ling; Beird, Hannah C.; Garber, Haven R.; Roh, Whijae; Wani, Khalida; Chen, Eveline; Haymaker, Cara; Forget, Marie Andrée; Little, Latasha D.; Gumbs, Curtis; Thornton, Rebecca L.; Hudgens, Courtney W.; Chen, Wei Shen; Austin-Breneman, Jacob; Sloane, Robert Szczepaniak; Nezi, Luigi; Cogdill, Alexandria P.; Bernatchez, Chantale; Roszik, Jason; Hwu, Patrick; Woodman, Scott E.; Chin, Lynda; Tawbi, Hussein; Davies, Michael A.; Gershenwald, Jeffrey E.; Amaria, Rodabe N.; Glitza, Isabella C.; Diab, Adi; Patel, Sapna P.; Hu, Jianhua; Lee, Jeffrey E.; Grimm, Elizabeth A.; Tetzlaff, Michael T.; Lazar, Alexander J.; Wistuba, Ignacio I.; Clise-Dwyer, Karen; Carter, Brett W.; Zhang, Jianhua; Futreal, P. Andrew; Sharma, Padmanee; Allison, James P.; Cooper, Zachary A.; Wargo, Jennifer A.

In: npj Genomic Medicine, Vol. 2, No. 1, 10, 01.12.2017.

Research output: Contribution to journalArticle

Reuben, A, Spencer, CN, Prieto, PA, Gopalakrishnan, V, Reddy, SM, Miller, JP, Mao, X, De Macedo, MP, Chen, J, Song, X, Jiang, H, Chen, PL, Beird, HC, Garber, HR, Roh, W, Wani, K, Chen, E, Haymaker, C, Forget, MA, Little, LD, Gumbs, C, Thornton, RL, Hudgens, CW, Chen, WS, Austin-Breneman, J, Sloane, RS, Nezi, L, Cogdill, AP, Bernatchez, C, Roszik, J, Hwu, P, Woodman, SE, Chin, L, Tawbi, H, Davies, MA, Gershenwald, JE, Amaria, RN, Glitza, IC, Diab, A, Patel, SP, Hu, J, Lee, JE, Grimm, EA, Tetzlaff, MT, Lazar, AJ, Wistuba, II, Clise-Dwyer, K, Carter, BW, Zhang, J, Futreal, PA, Sharma, P, Allison, JP, Cooper, ZA & Wargo, JA 2017, 'Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma', npj Genomic Medicine, vol. 2, no. 1, 10. https://doi.org/10.1038/s41525-017-0013-8
Reuben, Alexandre ; Spencer, Christine N. ; Prieto, Peter A. ; Gopalakrishnan, Vancheswaran ; Reddy, Sangeetha M. ; Miller, John P. ; Mao, Xizeng ; De Macedo, Mariana Petaccia ; Chen, Jiong ; Song, Xingzhi ; Jiang, Hong ; Chen, Pei Ling ; Beird, Hannah C. ; Garber, Haven R. ; Roh, Whijae ; Wani, Khalida ; Chen, Eveline ; Haymaker, Cara ; Forget, Marie Andrée ; Little, Latasha D. ; Gumbs, Curtis ; Thornton, Rebecca L. ; Hudgens, Courtney W. ; Chen, Wei Shen ; Austin-Breneman, Jacob ; Sloane, Robert Szczepaniak ; Nezi, Luigi ; Cogdill, Alexandria P. ; Bernatchez, Chantale ; Roszik, Jason ; Hwu, Patrick ; Woodman, Scott E. ; Chin, Lynda ; Tawbi, Hussein ; Davies, Michael A. ; Gershenwald, Jeffrey E. ; Amaria, Rodabe N. ; Glitza, Isabella C. ; Diab, Adi ; Patel, Sapna P. ; Hu, Jianhua ; Lee, Jeffrey E. ; Grimm, Elizabeth A. ; Tetzlaff, Michael T. ; Lazar, Alexander J. ; Wistuba, Ignacio I. ; Clise-Dwyer, Karen ; Carter, Brett W. ; Zhang, Jianhua ; Futreal, P. Andrew ; Sharma, Padmanee ; Allison, James P. ; Cooper, Zachary A. ; Wargo, Jennifer A. / Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. In: npj Genomic Medicine. 2017 ; Vol. 2, No. 1.
@article{b8ab949c66074047a9805fc95c0a65bb,
title = "Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma",
abstract = "Appreciation for genomic and immune heterogeneity in cancer has grown though the relationship of these factors to treatment response has not been thoroughly elucidated. To better understand this, we studied a large cohort of melanoma patients treated with targeted therapy or immune checkpoint blockade (n = 60). Heterogeneity in therapeutic responses via radiologic assessment was observed in the majority of patients. Synchronous melanoma metastases were analyzed via deep genomic and immune profiling, and revealed substantial genomic and immune heterogeneity in all patients studied, with considerable diversity in T cell frequency, and few shared T cell clones (<8{\%} on average) across the cohort. Variables related to treatment response were identified via these approaches and through novel radiomic assessment. These data yield insight into differential therapeutic responses to targeted therapy and immune checkpoint blockade in melanoma, and have key translational implications in the age of precision medicine.",
author = "Alexandre Reuben and Spencer, {Christine N.} and Prieto, {Peter A.} and Vancheswaran Gopalakrishnan and Reddy, {Sangeetha M.} and Miller, {John P.} and Xizeng Mao and {De Macedo}, {Mariana Petaccia} and Jiong Chen and Xingzhi Song and Hong Jiang and Chen, {Pei Ling} and Beird, {Hannah C.} and Garber, {Haven R.} and Whijae Roh and Khalida Wani and Eveline Chen and Cara Haymaker and Forget, {Marie Andr{\'e}e} and Little, {Latasha D.} and Curtis Gumbs and Thornton, {Rebecca L.} and Hudgens, {Courtney W.} and Chen, {Wei Shen} and Jacob Austin-Breneman and Sloane, {Robert Szczepaniak} and Luigi Nezi and Cogdill, {Alexandria P.} and Chantale Bernatchez and Jason Roszik and Patrick Hwu and Woodman, {Scott E.} and Lynda Chin and Hussein Tawbi and Davies, {Michael A.} and Gershenwald, {Jeffrey E.} and Amaria, {Rodabe N.} and Glitza, {Isabella C.} and Adi Diab and Patel, {Sapna P.} and Jianhua Hu and Lee, {Jeffrey E.} and Grimm, {Elizabeth A.} and Tetzlaff, {Michael T.} and Lazar, {Alexander J.} and Wistuba, {Ignacio I.} and Karen Clise-Dwyer and Carter, {Brett W.} and Jianhua Zhang and Futreal, {P. Andrew} and Padmanee Sharma and Allison, {James P.} and Cooper, {Zachary A.} and Wargo, {Jennifer A.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41525-017-0013-8",
language = "English (US)",
volume = "2",
journal = "npj Genomic Medicine",
issn = "2056-7944",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

AU - Reuben, Alexandre

AU - Spencer, Christine N.

AU - Prieto, Peter A.

AU - Gopalakrishnan, Vancheswaran

AU - Reddy, Sangeetha M.

AU - Miller, John P.

AU - Mao, Xizeng

AU - De Macedo, Mariana Petaccia

AU - Chen, Jiong

AU - Song, Xingzhi

AU - Jiang, Hong

AU - Chen, Pei Ling

AU - Beird, Hannah C.

AU - Garber, Haven R.

AU - Roh, Whijae

AU - Wani, Khalida

AU - Chen, Eveline

AU - Haymaker, Cara

AU - Forget, Marie Andrée

AU - Little, Latasha D.

AU - Gumbs, Curtis

AU - Thornton, Rebecca L.

AU - Hudgens, Courtney W.

AU - Chen, Wei Shen

AU - Austin-Breneman, Jacob

AU - Sloane, Robert Szczepaniak

AU - Nezi, Luigi

AU - Cogdill, Alexandria P.

AU - Bernatchez, Chantale

AU - Roszik, Jason

AU - Hwu, Patrick

AU - Woodman, Scott E.

AU - Chin, Lynda

AU - Tawbi, Hussein

AU - Davies, Michael A.

AU - Gershenwald, Jeffrey E.

AU - Amaria, Rodabe N.

AU - Glitza, Isabella C.

AU - Diab, Adi

AU - Patel, Sapna P.

AU - Hu, Jianhua

AU - Lee, Jeffrey E.

AU - Grimm, Elizabeth A.

AU - Tetzlaff, Michael T.

AU - Lazar, Alexander J.

AU - Wistuba, Ignacio I.

AU - Clise-Dwyer, Karen

AU - Carter, Brett W.

AU - Zhang, Jianhua

AU - Futreal, P. Andrew

AU - Sharma, Padmanee

AU - Allison, James P.

AU - Cooper, Zachary A.

AU - Wargo, Jennifer A.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Appreciation for genomic and immune heterogeneity in cancer has grown though the relationship of these factors to treatment response has not been thoroughly elucidated. To better understand this, we studied a large cohort of melanoma patients treated with targeted therapy or immune checkpoint blockade (n = 60). Heterogeneity in therapeutic responses via radiologic assessment was observed in the majority of patients. Synchronous melanoma metastases were analyzed via deep genomic and immune profiling, and revealed substantial genomic and immune heterogeneity in all patients studied, with considerable diversity in T cell frequency, and few shared T cell clones (<8% on average) across the cohort. Variables related to treatment response were identified via these approaches and through novel radiomic assessment. These data yield insight into differential therapeutic responses to targeted therapy and immune checkpoint blockade in melanoma, and have key translational implications in the age of precision medicine.

AB - Appreciation for genomic and immune heterogeneity in cancer has grown though the relationship of these factors to treatment response has not been thoroughly elucidated. To better understand this, we studied a large cohort of melanoma patients treated with targeted therapy or immune checkpoint blockade (n = 60). Heterogeneity in therapeutic responses via radiologic assessment was observed in the majority of patients. Synchronous melanoma metastases were analyzed via deep genomic and immune profiling, and revealed substantial genomic and immune heterogeneity in all patients studied, with considerable diversity in T cell frequency, and few shared T cell clones (<8% on average) across the cohort. Variables related to treatment response were identified via these approaches and through novel radiomic assessment. These data yield insight into differential therapeutic responses to targeted therapy and immune checkpoint blockade in melanoma, and have key translational implications in the age of precision medicine.

UR - http://www.scopus.com/inward/record.url?scp=85028422302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028422302&partnerID=8YFLogxK

U2 - 10.1038/s41525-017-0013-8

DO - 10.1038/s41525-017-0013-8

M3 - Article

C2 - 28819565

AN - SCOPUS:85028422302

VL - 2

JO - npj Genomic Medicine

JF - npj Genomic Medicine

SN - 2056-7944

IS - 1

M1 - 10

ER -